Welcome to our dedicated page for Optimizerx news (Ticker: OPRX), a resource for investors and traders seeking the latest updates and insights on Optimizerx stock.
OptimizeRx Corp (NASDAQ: OPRX) provides a dedicated news hub for tracking developments in healthcare technology and digital patient engagement solutions. This page aggregates official announcements, financial disclosures, and strategic updates from the leader in EHR-integrated pharma messaging.
Investors and industry professionals will find curated coverage of earnings reports, technology partnerships, product launches, and regulatory milestones. The resource serves as a centralized source for understanding OPRX's role in connecting pharmaceutical companies with healthcare providers through cloud-based communication platforms.
Key content categories include financial results, strategic alliances with EHR providers, technology innovations in digital health messaging, and industry recognition of platform advancements. All materials maintain factual accuracy and timeliness required for informed decision-making.
Bookmark this page for streamlined access to OptimizeRx's evolving position in medication adherence solutions and AI-driven healthcare communications. Regular updates ensure stakeholders stay informed about developments impacting the digital pharma marketing landscape.
OptimizeRx (Nasdaq: OPRX), a leading provider of healthcare technology solutions, has scheduled its first quarter 2025 earnings conference call for Monday, May 12, 2025, at 4:30 p.m. Eastern Time. The company will release its financial results for the period ended March 31, 2025, via press release before the call.
The conference call will include a management presentation followed by a Q&A session. Investors can join through multiple channels including toll-free (1-844-825-9789) and international (1-412-317-5180) numbers. A webcast option is also available, and the replay will be accessible for 12 months through the company's investor relations website.
OptimizeRx (Nasdaq: OPRX) has announced plans to appoint a new independent director to its Board during the second half of 2025, continuing its board refreshment initiative. This appointment will mark the third new director since 2020, following Catherine Klema (2024) and Gregory D. Wasson (2020) additions.
The company, which specializes in healthcare technology solutions connecting life sciences companies with healthcare professionals and patients, is seeking candidates with relevant expertise to complement current Board members and support the company's strategy execution. The Board currently consists of five directors.
Board Chairperson Lynn Vos highlighted the company's progress under new CEO Steve Silvestro, focusing on building market share and driving profitable revenue growth. The company aims to address key pharma challenges including digital brand visibility, reducing script abandonment rates, enhancing point-of-care interoperability, and supporting specialty medications transition.
OptimizeRx (OPRX) reported strong Q4 2024 results with revenue increasing 14% year-over-year to $32.3 million. Q4 gross profit grew 23% to $22.0 million with a 68% margin. Full-year 2024 revenue reached $92.1 million, up 29% from 2023.
The company doubled its DAAP deals from 24 in 2023 to 48 in 2024. Q4 non-GAAP net income was $5.5 million ($0.30 per diluted share), while Adjusted EBITDA increased 53% to $8.8 million. Full-year GAAP net loss was $(20.1) million.
Looking ahead, OptimizeRx provided 2025 guidance with expected revenue of at least $100 million and Adjusted EBITDA of at least $12 million. The company is transitioning DAAP customers to a subscription-based model for data services to improve margins and reduce business cyclicality.
OptimizeRx (Nasdaq: OPRX), a leading provider of healthcare technology solutions for life sciences companies, has confirmed receiving a notice of nominations from stockholder Whetstone Capital Advisors, . The notice indicates Whetstone's intention to nominate two candidates for election to the OptimizeRx Board of Directors at the company's 2025 Annual Meeting of Stockholders.
The OptimizeRx Board will review the nominations and provide their formal recommendation in the upcoming definitive proxy statement, which will be filed with the SEC and distributed to eligible voting stockholders. The company emphasized that no stockholder action is currently required, and the 2025 Annual Meeting date has not yet been scheduled.
OptimizeRx (Nasdaq: OPRX) has appointed Steve Silvestro as its new Chief Executive Officer, effective March 10, 2025. Silvestro, who has been with the company since 2019, brings over 20 years of experience in health technology and services.
Previously serving as Chief Commercial Officer, President, and interim CEO, Silvestro was unanimously selected by the independent Directors following a rigorous search process. During his tenure at OptimizeRx, he has been important in transforming the company from a single-solution digital marketing provider to an industry leader with omnichannel capabilities.
The new CEO's strategic priorities include:
- Focusing on operational excellence and customer satisfaction
- Expanding value proposition with pharmaceutical companies
- Increasing recurring revenue model
- Driving towards becoming a Rule of 40 company
- Creating new opportunities for profitable revenue growth
OptimizeRx (Nasdaq: OPRX), a leading provider of healthcare technology solutions for life sciences companies, has scheduled its Fourth Quarter and Full Year 2024 financial results conference call for March 12, 2025, at 8:30 a.m. ET. The company will release its financial results for the quarter ended December 31, 2024, via press release before the conference call. Management will host the call followed by a Q&A session. A replay will be accessible for 12 months through the Investors section of the OptimizeRx website.
OptimizeRx (Nasdaq: OPRX) announced that CEO William J. Febbo will depart the company effective December 31, 2024, with advisory services continuing through March 31, 2025. Stephen Silvestro, who has served as Chief Commercial Officer and President, has been appointed as interim CEO while the Board conducts a search for a permanent replacement.
During Febbo's nearly nine-year tenure, he transformed the company from a single point of care product to an omnichannel platform serving top pharmaceutical companies. The company reaffirmed its 2024 financial guidance, expecting results at the higher end of its revenue and adjusted EBITDA guidance range.
OptimizeRx Corp (Nasdaq: OPRX), a healthcare technology solutions provider, has announced its participation in two upcoming investor conferences in New York City. The company will attend the 13th Annual ROTH Technology Conference from November 19th-20th, 2024, at The Hard Rock Hotel, and Canaccord Genuity's 2024 CG MedTech, Diagnostics and Digital Health & Services Forum on November 21st, 2024, at The Westin NY Grand Central. Both events will feature one-on-one meeting formats with management.
OptimizeRx reported Q3 2024 financial results with revenue increasing 30% year-over-year to $21.3 million. Gross profit rose 37% to $13.4 million with a 63% margin. The company reported a GAAP net loss of $(9.1) million, while non-GAAP net income was $2.3 million. Adjusted EBITDA improved to $2.7 million from $0.9 million year-over-year. The company updated its 2024 guidance, expecting revenue between $88-92 million and Adjusted EBITDA of $8-10 million. Cash position strengthened to $16.1 million as of September 30, 2024.
OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of healthcare technology solutions, has scheduled its third quarter 2024 conference call for November 13, 2024, at 4:30 p.m. Eastern Time. The company will discuss financial results for the quarter ended September 30, 2024, which will be released before the call. Management will host the call followed by a Q&A session. The call will be accessible via toll-free and international numbers, with a webcast option available. A replay will be accessible for 12 months through the company's investor relations website.
